75
CALGARY — October 27, 2025 Leads & Copy — Hemostemix Inc. (TSXV:HEM) climbed 15 percent this month after reporting positive Phase 2 results for ACP-01, its stem cell therapy for critical limb ischemia and other vascular conditions.
The Calgary-based company said trial participants showed improved blood flow and reduced pain scores, with no serious adverse events. The data supports advancement to Phase 3 and opens the door to licensing discussions with global pharmaceutical partners.
CEO Thomas Smeenk said Hemostemix is preparing filings in Canada and the EU and will seek fast-track designation in the U.S. under regenerative medicine guidelines.
Shares have gained 52 percent since August.
